MinorOther dermatologicals (topical); peripheral vasodilators (systemic)×Calcineurin inhibitor (immunosuppressant)
Updated · Methodology
Mechanism
CYP3A4 metabolises tacrolimus in the liver and the gut wall. Tacrolimus itself inhibits this enzyme and is more than 98.8% bound to plasma proteins (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the liver, minoxidil is mainly conjugated with glucuronic acid. It does not bind to plasma proteins and causes no substantial change in glomerular filtration rate or renal plasma flow (minoxidil tablets SmPC, AEMPS). Between 1% and 2% of the applied dose of scalp foam or solution reaches the circulation (minoxidil scalp foam SmPC, AEMPS). By its own documents, minoxidil does not belong to any group the tacrolimus documents warn about (CYP3A4 inhibitors and inducers, highly protein-bound drugs, drugs harmful to the kidneys, drugs that raise potassium), and no document names the pair.
Symptoms
The documents describe no symptoms of this combination. Tacrolimus very commonly raises blood pressure, commonly causes oedema and hair loss, and rarely pericardial effusion (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Minoxidil tablets cause salt and water retention and oedema, and pericardial effusion in 3–5% of patients not on dialysis (minoxidil tablets SmPC, AEMPS). If the skin is damaged or the scalp product is misused, more minoxidil may be absorbed. At least in theory, systemic effects may then appear: low blood pressure, a fast heart rate, swelling of the hands and feet (minoxidil scalp foam SmPC, AEMPS).
Management
According to the documents, the combination is acceptable, and the doses of tacrolimus and minoxidil need no change. No document names the pair (tacrolimus SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, and European Medicines Agency, EMA; Prograf label, US Food and Drug Administration, FDA; minoxidil SmPCs, AEMPS; minoxidil tablets label, FDA). Hypertension caused by tacrolimus can be controlled with any of the common antihypertensive agents. Only those associated with hyperkalaemia need careful consideration before use: potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (Prograf label, FDA). In the early post-transplant period, monitor blood pressure, potassium and other electrolytes, and kidney and liver function routinely (tacrolimus SmPC, AEMPS). Tacrolimus can impair kidney function, and in renal impairment minoxidil tablets may need a lower dose. With the tablets, monitor body weight and fluid and electrolyte balance (tacrolimus and minoxidil tablets SmPCs, AEMPS). Fluid overload and oedema are among the risk factors for myocardial hypertrophy during tacrolimus treatment. High-risk patients have echocardiography or an electrocardiogram (ECG) before and after transplantation, for example at baseline, at 3 months and at 9–12 months (tacrolimus SmPC, AEMPS). Minoxidil tablets cause salt and water retention, so they are taken together with a diuretic. Echocardiography is done at any sign of pericardial effusion (minoxidil tablets SmPC, AEMPS). With scalp minoxidil, blood pressure and heart rate are monitored regularly. The product is stopped if any of the following appear: low blood pressure, chest pain, a fast heart rate, weakness or dizziness, sudden weight gain, or swelling of the hands or feet (minoxidil scalp solution and foam SmPCs, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Prograf 0,5 mg cápsulas duras (tacrolimus) (2026)– AEMPS, CIMA, nº registro 63189, secciones 4.4 y 4.5
- FDA: Prograf (tacrolimus) prescribing information (2025)– Astellas Pharma US. PROGRAF (tacrolimus) capsules, injection, granules. Prescribing information, DailyMed setid 7f667de1-9dfa-4bd6-8ba0-15ee2d78873b, sections 4, 5.11 and 7
- EMA: Ficha técnica: Tacrolimus, Advagraf (EU/1/07/387), sección 4.5 (2026)– EMA SmPC vía AEMPS CIMA, nº registro 07387017 (EU/1/07/387), sección 4.5, texto vigente consultado 10/2026
- AEMPS: Ficha técnica: Minoxidil, Regaine 50 mg/g espuma cutánea (nº registro 76483), sección 4.4 (2025)– AEMPS, CIMA, nº registro 76483 (Regaine 50 mg/g espuma cutánea, JNTL Consumer Health), revisión 09/2025, secciones 4.1, 4.4, 4.5, 4.8 y 5.2
- AEMPS: Ficha técnica: Minoxidil, Loniten 10 mg comprimidos (nº registro 55636), sección 4.4 (2020)– AEMPS, CIMA, nº registro 55636 (Loniten 10 mg comprimidos, Pfizer), revisión 11/2020, secciones 4.1, 4.2, 4.4, 4.5 y 5.2
- FDA: Minoxidil tablets, Sun Pharmaceutical (minoxidil) prescribing information (2026)– FDA, DailyMed setid 0354a7f5-5917-44dc-9963-411104008cb5 (Sun Pharmaceutical Industries), versión 5, 02/2026, Warnings, Precautions (General, Drug interactions, Unapproved use), Clinical Pharmacology
- AEMPS: Ficha técnica: Minoxidil, Lacovin 20 y 50 mg/ml solución cutánea (nº registro 66881), sección 4.4 (2024)– AEMPS, CIMA, nº registro 66881 (Lacovin 20 y 50 mg/ml solución cutánea, Galderma), revisión 09/2024, secciones 4.4, 4.5 y 5.2